Cited by 254Antifungal resistance and susceptibilityFungal Infections and StudiesHIV/AIDS oral health manifestations

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases

Open access

Arathoon, Eduardo G., Gotuzzo, Eduardo, Noriega, L. Miguel, Berman, Rayanne S., DiNubile, Mark J., Sable, Carole A.·2002·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.46.2.451-457.2002PMC PMC127070

Open this paper in CoChat — free account

Abstract

Caspofungin is an antifungal agent of the novel echinocandin class. We investigated its efficacy, safety, and tolerability as therapy for oropharyngeal and/or esophageal candidiasis in a phase II dose-ranging study. Patients were randomized in a double-blind manner to receive either caspofungin acetate (35, 50, or 70 mg) or amphotericin B (0.5 mg/kg of body weight) intravenously once daily for 7 to 14 days. A favorable response required both complete resolution of symptoms and quantifiable improvement of mucosal lesions 3 to 4 days after discontinuation of study drug. Efficacy was assessed using a modified intent-to-treat analysis. No hypothesis testing of efficacy was planned or performed. Of 140 enrolled patients, 63% had esophageal involvement and 98% were infected with the human immunodeficiency virus (HIV) (median CD4 count, 30/mm(3)). A modestly higher proportion of patients in each of the caspofungin groups (74 to 91%) achieved favorable responses compared to amphotericin B recipients (63%), but there was considerable overlap in the 95% confidence intervals surrounding these point estimates. Similar trends were found in the subgroups with esophageal involvement, a history of fluconazole failure, and CD4 counts of < or =50/mm(3). A smaller proportion of patients receiving any dose of caspofungin experienced drug-related adverse events compared to patients given standard doses of conventional amphotericin B (P < 0.01). Caspofungin provided a generally well-tolerated parenteral therapeutic option for HIV-infected patients with oropharyngeal and/or esophageal candidiasis in this study.

Integrity signals

Registry

Crossref · 10.1128/aac.46.2.451-457.2002

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Epidemiology of Human Immunodeficiency Virus–Associated Opportunistic Infections in the United States in the Era of Highly Active Antiretroviral Therapy
Kaplan, J. E., Hanson, D. L., Dworkin, M. S., Frederick, T., Bertolli, J., Lindegren, M. L., Holmberg, S. D., & Jones, J. L. (2000) · Clinical Infectious Diseases · doi:10.1086/313843 · Cited by 703
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance
Sangeorzan, J. A., Bradley, S. F., He, X., Zarins, L. T., Ridenour, G. L., Tiballi, R. N., & Kauffman, C. A. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90300-x · Cited by 322
International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
Pfaller, M. A., Jones, R. N., Doern, G. V., Fluit, A. C., Verhoef, J., Sader, H. S., Messer, S. A., Houston, A. K., Coffman, S. L., & Hollis, R. J. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00046-2 · Cited by 264
Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection
Ruhnke, M., Eigler, A., Tennagen, I., Geiseler, B., Engelmann, E., & Trautmann, M. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.9.2092-2098.1994 · Cited by 250
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
Abruzzo, G. K., Flattery, A. M., Gill, C. J., Kong, L., Smith, J. G., Pikounis, V. B., Balkovec, J. M., Bouffard, A., Dropinski, J. F., Rosen, H., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2333 · Cited by 241
Esophageal infections: Risk factors, presentation, diagnosis, and treatment
Baehr, P. H., & McDonald, G. B. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90613-0 · Cited by 214
Current and future antifungal therapy: new targets for antifungal agents
Andriole, V. T. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.2.151 · Cited by 191

Flagged first, then by citations

Show all 46 references

Sorted by citations

Items 201–254 of 254

Antifungal Therapy for Invasive Fungal Infections
Badali, H., Khodavaisy, S., Davoudi, M. M., Biranvand, E., & Mardani, M. (2014) · Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Māzandarān/Journal of Mazandaran University of Medical Sciences · Cited by 2
Glucan Synthase Inhibitors
Gumbo, T., Ikeda, F., & Louie, A. (2007) · Infectious disease and therapy · doi:10.3109/9781420017137.018 · Cited by 2
Antifungal Drugs
Bustamante, B., Hidalgo, J. A. M., & Campos, P. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-64113-3_2 · Cited by 2
Systemic Antifungal Agents
Stevens, D. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00339-0 · Cited by 2
Reply
DiNubile, M. J., & Sable, C. A. (2002) · Clinical Infectious Diseases · doi:10.1086/340720 · Cited by 2
Self-citation
Utilidad clínica de la anidulafungina en el tratamiento de las candidiasis esofágicas, candidemias y candidiasis invasoras
González, J. C. M., González, M. C., & Gil, C. L. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70028-7 · Cited by 2
Outpatient Parenteral Antimicrobial Therapy
Tice, A. D. (2010) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-0-443-06839-3.00048-5 · Cited by 1
Antifungal Therapy in The ICU: The Bug, the Drug, and the Mug
Pereira, J. M., & Paiva, J. A. (2011) · Annual update in intensive care and emergency medicine · doi:10.1007/978-3-642-18081-1_47 · Cited by 1
Antifungal Therapy in the Intensive Care Unit
Paiva, J. A., & Pereira, J. M. (2007) · Springer eBooks · doi:10.1007/978-3-540-34406-3_11 · Cited by 1
Retrospective evaluation of caspofungin therapy in invasive aspergillosis (RECAM-IA)
Wisniewski, T., Климко, Н. Н., Laverdière, M., Kiertiburanakul, S., Klyasova, G. A., Trenschel, R., & Kumar, R. N. (2010) · Mycoses · doi:10.1111/j.1439-0507.2010.01861.x · Cited by 1
Dermatophytosis
Keiler, S. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-16 · Cited by 1
Caspofungin und Voriconazol Zwei neue Antimykotika
Masche, U. (2004) · pharma-kritik · doi:10.37667/pk.2004.96 · Cited by 1
Esophagitis
GRAMAN, P. S. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00099-0 · Cited by 1
ANTIFUNGAL AGENTS
Groll, A. H., & Walsh, T. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50257-0 · Cited by 1
Invasive fungal infections in children: advances and perspectives
Groll, A. H., Köhler, J. R., & Walsh, T. J. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8099-1_16 · Cited by 1
Echinocandins: Exploring Susceptibility and Resistance
Douglas, C. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-180-2_28 · Cited by 1
Infektionserkrankungen
Bialek, R., Groll, A. H., Heininger, U., & Schuster, V. H. (2007) · Elsevier eBooks · doi:10.1016/b978-343723200-8.50020-2 · Cited by 1
Caspofungin exposure‐response relationships in adult patients with mucosal or invasive candidiasis
Comisar, W. A., Sun, P. G., Li, S., Sable, C. A., Schwartz, M. S., Bi, S., Chow, J. W., Ngai, A. L., Winchell, G. A., Kartsonis, N. A., et al. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.44 · Cited by 1
Self-citation
Safety and Efficacy Data for High-Dose Caspofungin
Klepser, M. E. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0017-7 · Cited by 1
Management of Resistant Candida Infections
Clements, S., & Kibbler, C. C. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-738-3_16 · Cited by 1
Caspofungine, place dans les stratégies thérapeutiques antifongiques
Leroy, O., & Ajana, F. (2004) · Antibiotiques · doi:10.1016/s1294-5501(04)94254-9 · Cited by 1
Atemwegsinfektionen bei immunsupprimierten Personen
Stockschläder, M., Montemurro, M., Kiefer, T., & Dölken, G. (2003) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-002-0536-7 · Cited by 1
Démarche diagnostique et prise en charge des infections fongiques chez les patients immunodéprimés
Botterel, F. (2007) · Antibiotiques · doi:10.1016/s1294-5501(07)88765-6 · Cited by 1
Antifungal Therapy in Surgical ICU Patients
Weigand, M. A., Lichtenstern, C., & Böttiger, B. W. (2006) · Yearbook of intensive care and emergency medicine · doi:10.1007/3-540-33396-7_57 · Cited by 1
Antifungal Drug Resistance: Clinical Importance, in vitro Detection and Implications for Prophylaxis and Treatment
Arthington, B. A., & Frade, J. P. (2010) · Issues in infectious diseases · doi:10.1159/000298761
Antifungal-Induced Nephrotoxicity in Pediatrics: A State of the Art
Fanos, V., Zaffanello, M., Cuzzolin, L., & Cataldi, L. (2010) · Springer eBooks · doi:10.1007/978-3-642-12173-9_6
Discovery and Development of Caspofungin (CANCIDAS): Concept to Clinic
Balkovec, J. M., Hughes, D. L., Masurekar, P. S., Sable, C. A., Schwartz, R. E., & Singh, S. B. (2014) · doi:10.1002/9781118794623.ch27
Self-citation
Qualitative Bestimmung von Candida-Spezies in der Mundhöhle bei Patienten nach Herz-, Leber- und Lungentransplantation
Kießling, C. (2005) · edoc Publication server (Humboldt University of Berlin) · doi:10.18452/15231
L’anidulafungine – Une nouvelle échinocandine dans les candidoses invasives
Lortholary, O. (2007) · Réanimation · doi:10.1016/s1624-0693(07)78762-5
Nouvelles approches thérapeutiques des infections fongiques : place des nouvelles molécules
Montravers, P., Chterev, V., Augustin, P., & Etchegoyen, L. (2008) · Antibiotiques · doi:10.1016/j.antib.2007.12.003
Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins
Neoh, C. F., Kong, D. C. M., Slavin, M. A., & Chen, S. C.-A. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0085-y
Australasian guidelines for antifungal therapy in neonates and children with proven, probable and suspected invasive fungal infections
Blyth, C., & Blyth, C. C. (2007)
An evaluation of intravenous antifungal medications in patients in a paediatric hospital
Rajan, R. T. (2008) · eSpace (Curtin University)
Antifungals for Candidosis Treatment
Grégio, A. M. T., Veiga, F. F., Rinaldi, M. G., & Bettega, P. V. C. (2015) · Springer eBooks · doi:10.1007/978-3-662-47194-4_4
Echinocandins – Caspofungin, Anidulafungin and Micafungin
Lewis, R. E., & Kontoyiannis, D. P. (2010) · CRC Press eBooks · doi:10.1201/b13787-145
Spectrum of Activity, Pharmacology, and Clinical Indications
Nett, J. E., & Andes, D. R. (2015)
Neue Medikamente zur Behandlung systemischer Mykosen
SCHEDEL, I. (2005) · Der Internist · doi:10.1007/s00108-005-1413-x
Antifungal tedavide son gelişmeler
Kaan, K. (2008) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.1501/eczfak_0000000491
Drug-induced Injury, Infections, and Congenital and Miscellaneous Disorders
Mounajjed, T. (2019) · Springer eBooks · doi:10.1007/978-3-030-15573-5_5
AIDS-Related Mycoses
Bicanic, T. A., Logan, C., Gómez, B. L., Le, T. P., & Wasserman, S. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819990-9.00057-3
Echinocandins
Lepak, A. J., & Andes, D. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819990-9.00018-4
Esophagitis
GRAMAN, P. S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00094-1
Amphotericin
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00286-9
Echinocandins
(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00515-5
The esophagus
Yantiss, R. K. (2015) · Cambridge University Press eBooks · doi:10.1017/9781139137201.025
ANTIFUNGAL DRUGS
(2010) · Elsevier eBooks · doi:10.1016/b978-0-444-53272-5.50007-8
Amphotericin
(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00513-1
Echinocandins for Prevention and Treatment of Invasive Fungal Infections
Johnson, M. D., & Mohr, J. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-14
Echinocandins
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00672-7
Antifungal drugs
Groll, A. H., Kolve, H., & Walsh, T. J. (2004) · Side effects of drugs annual · doi:10.1016/s0378-6080(04)80034-5
Candidiasis Treatment: An Evolutionary Journey from Past to Present and a Glimpse into the Future
Bappy, M. N. I., Robin, T. B., & Zinnah, K. M. A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_3
Antifungal Agents
Groll, A. H., & Walsh, T. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00256-9
Oral Candidiasis
Delaney, C., Abduljalil, H., Shaban, S. M. A., Alshehri, M., & Brown, J. L. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_1
Three decades of pneumocandin research: Derivatives, structural insights, and strain engineering
Baldia, A., Rajput, D., & Dubey, K. K. (2026) · Bioresource Technology Reports · doi:10.1016/j.biteb.2026.102575

Authors: Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., & Sable, C. A.
Affiliations: Hospital General San Juan de Dios (GT)
Hospital Nacional Cayetano Heredia (PE)
Complejo Asistencial Sótero del Río (CL)
Merck Research Laboratories, West Point, Pennsylvania
Corresponding author: DiNubile, Mark J.
ORCID: Arathoon, Eduardo G.
Gotuzzo, Eduardo
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2002-02
Volume: 46
Issue: 2
Pages: 451-457
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.46.2.451-457.2002
PMC: PMC127070
OpenAlex: W2156228013
Cited by: 254
References: 46
Citations by year: 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 6 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 1 · 2015: 8 · 2014: 8 · 2013: 4 · 2012: 7
FWCI: 18.98
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Health Sciences › Dentistry › General Dentistry › HIV/AIDS oral health manifestations
Keywords: caspofungin, amphotericin B, oropharyngeal candidiasis, esophageal candidiasis, HIV infection, CD4 count, drug safety and tolerability, dose-ranging
MeSH terms: Caspofungin, Adolescent, Adult, Aged, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Candidiasis, Double-Blind Method, Drug Tolerance, Esophageal Diseases, Female, Humans, Male, Middle Aged, Peptides, Peptides, Cyclic, Pharyngeal Diseases, Treatment Outcome, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks